Launch of the ALMA project: Artificial Intelligence for diagnosis, treatment and prognosis of hematological diseases

Time to read:

3 minutes

Hospital 12 de Octubre, together with the Vall de Hebron Hospital Cancer Research Institute, Hospital Clínico San Carlos, Universidad Politécnica de Madrid-CIBER-BBN, Universidad Complutense de Madrid and SpotLab, a company dedicated to artificial intelligence and health, are launching the ALMA project for the use of artificial intelligence algorithms for diagnosis, treatment and prognosis of hematological diseases, promoted by the Strategic Program for Recovery and Economic Transformation (PERTE) for Vanguard Health, treatment and prognosis of hematological diseases, promoted by the Strategic Program for Economic Recovery and Transformation (PERTE) for Vanguard Health through the Carlos III Health Institute (ISCIII) and the Center for Technological Development and Innovation (CDTI).

The ALMA project seeks to integrate innovative artificial intelligence tools in the field of personalized medicine applied to hematological diseases. The public-private consortium will investigate new AI algorithms to quantify and discover patterns in clinical data and bone marrow images to aid in earlier and more accurate diagnosis and prediction of response to treatment of diseases such as acute myeloid leukemia or myelodysplastic syndrome.

The industrial partner of the ALMA consortium is SpotLab, an artificial intelligence company for medicine based in Madrid. Miguel Luengo Oroz, CEO of SpotLab says:

 The development of safe and reliable AI opens new horizons in medicine toward more accurate diagnosis and treatment. In the future, physicians will also be conductors of AI algorithms.

The ALMA project is based on technology developed over more than 4 years and recently presented at the American Congress of Hematology (ASH). Spotlab’s AI technology is supported by the Bill & Melinda Gates Foundation and the European Union, among others, and is present in Europe, Africa and Latin America.

The multidisciplinary teams of the ALMA consortium met in Madrid on May 17 at UPM and Spotlab for the launch of the project. More than 35 researchers including hematologists, biochemists, engineers and artificial intelligence experts shared the plans and early results of the project. They also worked in sessions to incorporate the most novel aspects of AI language models as an assistant to clinical practice in hematology.

The ALMA project seeks to advance personalized medicine and lays the groundwork for future innovations in the use of artificial intelligence for hematological diseases. This artificial intelligence system is expected to contribute to improved diagnostic accuracy, effective treatment selection and patient prognosis. ALMA is driven by the Instituto de Salud Carlos III (ISCIII), the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) and the European Union NextGenerationEU, which are funding the actions of the Mechanism for Recovery and Resilience (MRR).

Check out the press releases of our partners:


SpotLab is a social enterprise that seeks to democratize access to quality diagnostics by bringing artificial intelligence to diseases that are not yet in the digital world. To make this possible, we use exponential and affordable technologies – smartphones, AI and 3D printing – to reduce the time, cost, distance and CO2 footprint of medical diagnostics. Our technology is present in Europe, Latin America and Africa. For more information, please visit us at

ALMA project participants

ALMA está impulsado por el Instituto de Salud Carlos III (ISCIII) y el Centro para el Desarrollo Tecnológico y la Innovación (CDTI), y cuenta con financiación del Mecanismo para la Recuperación y la Resiliencia (MRR) y de NextGenerationEU de la Unión Europea.